RESUMEN

OBJECTIVE: We aimed to describe characteristics of patients with ATTR variant polyneuropathy (ATTRv-PN) and ATTRv-mixed and assess the real-world use and safety profile of tafamidis meglumine 20mg. METHODS: Thirty-eight French hospitals were invited. Patient files were reviewed to identify clinical manifestations, diagnostic methods, and treatment compliance. RESULTS: Four hundred and thirteen patients (296 ATTRv-PN, 117 ATTRv-mixed) were analyzed. Patients were predominantly male (68.0%) with a mean age of 57.2±17.2 years. Interval between first symptom(s) and diagnosis was 3.4±4.3 years. First symptoms included sensory complaints (85.9%), dysautonomia (38.5%), motor deficits (26.4%), carpal tunnel syndrome (31.5%), shortness of breath (13.3%), and unexplained weight loss (16.0%). Mini-invasive accessory salivary gland or punch skin and nerve biopsies were most common, with a performance of 78.8-100%. TTR genetic sequencing, performed in all patients, revealed 31 TTR variants. Tafamidis meglumine was initiated in 156/214 (72.9%) ATTRv-PN patients at an early disease stage. Median treatment duration was 6.00 years in ATTRv-PN and 3.42 years in ATTRv-mixed patients. Tafamidis was well tolerated, with 20 adverse events likely related to study drug among the 336 patients. CONCLUSION: In France, ATTRv patients are usually identified early thanks to the national network and the help of diagnosis combining genetic testing and mini-invasive biopsies.

Asunto(s)

Neuropatías Amiloides Familiares , Benzoxazoles , Humanos , Masculino , Francia/epidemiología , Femenino , Persona de Mediana Edad , Anciano , Neuropatías Amiloides Familiares/diagnóstico , Neuropatías Amiloides Familiares/tratamiento farmacológico , Neuropatías Amiloides Familiares/genética , Neuropatías Amiloides Familiares/epidemiología , Estudios Transversales , Adulto , Benzoxazoles/uso terapéutico , Benzoxazoles/efectos adversos , Anciano de 80 o más Años , Prealbúmina/genética

RESUMEN

BACKGROUND AND PURPOSE: The aim is to describe an uncommon phenotype of hereditary ATTR neuropathy with upper limb onset. METHODS: The French TTR Familial Amyloid Polyneuropathy database was used for a retrospective evaluation of 32 consecutive patients with upper limb onset of the neuropathy (study group) and they were compared to 31 Portuguese early-onset patients and 99 late-onset patients without upper limb onset. RESULTS: Initial upper limb symptoms were mostly sensory. Lower limb symptoms began 2.3 ± 3 years after upper limb symptoms. Twenty-four (75%) patients were initially misdiagnosed, with 15 different diagnoses. More patients in the study group had a Neuropathy Impairment Score upper limb/lower limb ratio > 1 compared to the late-onset patient group. The study group had significantly more pronounced axonal loss in the median and ulnar motor nerves and the ulnar sensory and sural nerves. On radial nerve biopsies (n = 11), epineurial vessels were abnormal in six cases, including amyloid deposits in vessel walls (3/11), with vessel occlusion in two cases. CONCLUSION: Upper limb onset of hereditary ATTR neuropathy is not rare in non-endemic areas. It is important to propose early TTR sequencing of patients with idiopathic upper limb neuropathies, as specific management and treatment are required.

Asunto(s)

Neuropatías Amiloides Familiares , Extremidad Superior , Anciano , Neuropatías Amiloides Familiares/diagnóstico , Neuropatías Amiloides Familiares/epidemiología , Neuropatías Amiloides Familiares/patología , Neuropatías Amiloides Familiares/fisiopatología , Femenino , Francia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos

RESUMEN

INTRODUCTION: Bladder exstrophy is a rare, congenital, complex malformation where the underlying cause is largely unknown. Both environmental and genetic mechanisms are thought to be involved. There are divergent results concerning the prevalence, birth descriptive data, and potential maternal risk factors for bladder exstrophy. Few previous studies have reflected nationwide populations, population registers, or spanned a longer period of time. OBJECTIVE: To describe and assess bladder exstrophy and the potential maternal risk factors, for a time period of four decades, by conducting a nationwide register study of bladder exstrophy in Sweden. METHODS: A matched-design, case-control, linkage-analysis study nested within the entire pool of live births in Sweden between 1973 and 2011 was performed. Cases with bladder exstrophy were identified using nationwide population-based birth and health registers. Inclusion criteria were people born in Sweden with the classification of bladder exstrophy according to the ICD coding system. Cases were matched with five controls per patient, based on birth year and sex. Prevalence was assessed and birth descriptive data were compiled. Potential maternal risk factors were obtained from medical birth registers of cases and assessed using conditional and multivariate logistic regression models to obtain odds ratios as a measure of the relative risk. Classification of the diagnosis in the registers constituted a possible limitation for determining the correct study population, which demanded strict validation and inclusion criteria. All data were collected prospectively, thereby avoiding potential recall bias. RESULTS: The prevalence was calculated to be approximately 3 per 100,000 live births, with a male-to-female ratio of 1.14:1. In 92.5% of the cases, bladder exstrophy was an isolated malformation without associated major malformations. However, 41% had had surgery for congenital inguinal hernia and 11% of the male subjects had been operated on for cryptorchidism. A significantly higher proportion of cases had a birth weight <1500 g compared with controls, but other characteristics were comparable with controls. High maternal age was the only significant potential associated maternal risk factor. CONCLUSIONS: One hundred and twenty children born with bladder exstrophy in Sweden during the last four decades were identified; this resulted in prevalence in Sweden of 3 per 100,000. The prevalence was stable over time and the sex ratio was equal. Birth characteristics were comparable to controls, and bladder exstrophy generally occurred as an isolated malformation without major associated malformations. Advanced maternal age was the only significant potential maternal risk factor.

Asunto(s)

Extrofia de la Vejiga/epidemiología , Adulto , Estudios de Casos y Controles , Femenino , Feto , Humanos , Recién Nacido , Masculino , Edad Materna , Embarazo , Complicaciones del Embarazo/epidemiología , Prevalencia , Factores de Riesgo , Suecia , Adulto Joven

RESUMEN

Premature ovarian insufficiency (POI) affects approximately 1% of women before the age of 40. Genetic contribution is a significant component of POI. In this context, heterozygous mutations in NOBOX, BMP15 and GDF9 have been reported. The objective of our study was to evaluate the prevalence of these genes mutations in 125 unrelated Tunisian patients diagnosed with POI. The screening of NOBOX gene revealed three missense mutations (p.Arg117Trp; p.Gly91Trp and p.Pro619Leu) in eight patients. These mutations were not found in a 200 ethnically matched women without fertility problem. The sequencing of BMP15 and GDF9 gene revealed only previously reported variants. In contrast to previous studies, the prevalence of BMP15 variations is not higher than in the control population. Conversely, 6.4% of the cases present a NOBOX mutations; this high prevalence strengthens the consideration of NOBOX gene as strong autosomal candidate for POI.

Asunto(s)

Predisposición Genética a la Enfermedad/genética , Proteínas de Homeodominio/genética , Mutación Missense , Insuficiencia Ovárica Primaria/genética , Factores de Transcripción/genética , Adulto , Alelos , Análisis Mutacional de ADN , Femenino , Frecuencia de los Genes , Pruebas Genéticas/métodos , Pruebas Genéticas/estadística & datos numéricos , Genotipo , Humanos , Prevalencia , Insuficiencia Ovárica Primaria/diagnóstico , Insuficiencia Ovárica Primaria/epidemiología , Túnez/epidemiología

RESUMEN

Interstitial duplication within the long arm of chromosome 20 is an uncommon chromosome structural abnormality. We report here the clinical and molecular characterization associated with pure 20q13.2 duplication in three unrelated patients. The most frequent clinical features were developmental delay, facial dysmorphism, cardiac malformation and skeletal anomalies. All DNA gains occurred de novo, ranging from 1.1 Mb to 11.5 Mb. Compared with previously reported conventional cytogenetic analyses, oligonucleotides array CGH allowed us to refine breakpoints and determine the genes of interest in the region. Involvement of SALL4 in cardiac malformations and NFATC2 gene disruption in both cardiac and skeletal anomalies are discussed.

Asunto(s)

Anomalías Múltiples/genética , Cromosomas Humanos Par 22/genética , Duplicación de Gen , Factores de Transcripción NFATC/genética , Factores de Transcripción/genética , Preescolar , Aberraciones Cromosómicas , Hibridación Genómica Comparativa , Anomalías Craneofaciales/genética , Discapacidades del Desarrollo/genética , Femenino , Enfermedades Fetales/genética , Cardiopatías Congénitas/genética , Humanos , Hibridación Fluorescente in Situ , Cariotipo , Masculino , Adulto Joven

RESUMEN

Small supernumerary marker chromosomes (sSMC) are structurally abnormal chromosomes that cannot be unambiguously identified by conventional banding cytogenetics. This study describes four patients with sSMC in relation with infertility. Patient 1 had primary infertility. His brother, fertile, carried the same sSMC (patient 2). Patient 3 presented polycystic ovary syndrome and patient 4 primary ovarian insufficiency. Cytogenetic studies, array comparative genomic hybridization (CGH) and sperm analyses were compared with cases previously reported. sSMC corresponded to the 15q11.2 region (patients 1 and 2), the centromeric chromosome 15 region (patient 3) and the 21p11.2 region (patient 4). Array CGH showed 3.6-Mb gain for patients 1 and 2 and 0.266-Mb gain for patient 4. Sperm fluorescent in-situ hybridization analyses found ratios of 0.37 and 0.30 of sperm nuclei with sSMC(15) for patients 1 and 2, respectively (P < 0.001). An increase of sperm nuclei with disomy X, Y and 18 was noted for patient 1 compared with control and patient 2 (P < 0.001). Among the genes mapped in the unbalanced chromosomal regions, POTE B and BAGE are related to the testis and ovary, respectively. The implication of sSMC in infertility could be due to duplication, but also to mechanical effects perturbing meiosis.

Asunto(s)

Aberraciones Cromosómicas , Hibridación Genómica Comparativa/métodos , Marcadores Genéticos/genética , Infertilidad Femenina/genética , Infertilidad Masculina/genética , Adulto , Citogenética , Femenino , Eliminación de Gen , Humanos , Hibridación Fluorescente in Situ/métodos , Masculino , Síndrome del Ovario Poliquístico/genética , Reacción en Cadena de la Polimerasa/métodos , Espermatozoides/metabolismo

RESUMEN

Oral, but not transdermal, estrogen therapy increases the risk of venous thromboembolism (VTE) in women who are past menopause. Data from the Estrogen and Thromboembolism Risk (ESTHER) study were used to investigate the effects of the genetic polymorphism of NFE2L2 rs6721961, which may impair Nrf2-dependent hepatic conjugation of estrogen metabolites. As compared with nonusers, the odds ratio (OR) for VTE in current users of oral estrogens was 2.5 (95% confidence interval (CI): 1.3-4.8) in patients with wild-type NFE2L2 and 17.9 (95% CI: 3.7-85.7) in those with the polymorphism (interaction, P = 0.01).

Asunto(s)

Terapia de Reemplazo de Estrógeno/efectos adversos , Factor 2 Relacionado con NF-E2/genética , Polimorfismo de Nucleótido Simple , Posmenopausia , Tromboembolia Venosa/genética , Administración Cutánea , Administración Oral , Anciano , Estudios de Casos y Controles , Estradiol/administración & dosificación , Estradiol/efectos adversos , Estradiol/farmacocinética , Estradiol/uso terapéutico , Estrógenos/administración & dosificación , Estrógenos/efectos adversos , Estrógenos/farmacocinética , Estrógenos/uso terapéutico , Femenino , Estudios de Asociación Genética , Humanos , Fase II de la Desintoxicación Metabólica/genética , Persona de Mediana Edad , Oportunidad Relativa , Embolia Pulmonar/epidemiología , Embolia Pulmonar/genética , Factores de Riesgo , Tromboembolia Venosa/epidemiología , Trombosis de la Vena/epidemiología , Trombosis de la Vena/genética

RESUMEN

We report on the high yield connection of single nano-objects as small as a few nanometres in diameter to separately elaborated metallic electrodes, using a 'table-top' nanotechnology. Single-electron transport measurements validate that transport occurs through a single nano-object. The vertical geometry of the device natively allows an independent choice of materials for each electrode and the nano-object. In addition ferromagnetic materials can be used without encountering oxidation problems. The possibility of elaborating such hybrid nanodevices opens new routes for the democratization of spintronic studies in low dimensions.

RESUMEN

Congenital hypogonadotropic hypogonadisms (CHH) are a well-known cause of pubertal development failure in women. In a majority of patients, the clinical spectrum results from an insufficient and concomitant secretion of both pituitary gonadotropins LH and FSH that impedes a normal endocrine and exocrine cyclical ovary functioning after the age of pubertal activation of gonadotropic axis. In exceptional but interesting cases, they can result from an elective deficit of one of the gonadotropins follicle-stimulating hormone (FSH) or luteinizing hormone (LH) by genetic anomaly of their specific ss sub-unit. CHH prevalence, estimated from teaching hospital series, is considered to be two to five fold less important in women compared to men bearing the disease. This frequency is probably under-estimated in reason of under-diagnosis of forms with partial pubertal development. Isolated or apparently isolated forms (i.e., Kallmann syndrome with anosmia or hyposmia not spontaneously expressed by the patients) of these diseases are most of the time discovered during adolescence or in adulthood in reason of lacking, incomplete or even apparently complete pubertal development, but with almost constant primary amenorrhea. In a minority of cases and mainly in familial forms, genetic autosomal causes have been found. These cases are related to mutations of genes impinging the functioning of the pituitary-hypothalamic pathways involved in the normal secretion of LH and FSH (mutations of GnRHR, GnRH1, KISS1R/GPR54, TAC3, TACR3), which are always associated to isolated non syndromic CHH without anosmia. Some cases of mutations of FGFR1, and more rarely of its ligand FGF8, or of PROKR2 or its ligand PROK2 have been shown in women suffering from Kallmann syndrome or its hyposmic or normosmic variant. In complex syndromic causes (mutations of CHD7, leptin and leptin receptor anomalies, Prader-Willi syndrome, etc.), diagnosis of the CHH cause is most often suspected or set down before the age of puberty in reason of the associated clinical signs, but some rare cases of paucisymptomatic syndromic causes can initially be revealed during adolescence, like isolated non syndromic CHH or Kallmann syndrome.

Asunto(s)

Hipogonadismo/genética , Femenino , Factor 8 de Crecimiento de Fibroblastos/genética , Hormona Folículo Estimulante/deficiencia , Hormona Folículo Estimulante/genética , Hormona Folículo Estimulante/fisiología , Hormonas Gastrointestinales/genética , Humanos , Hipogonadismo/fisiopatología , Síndrome de Kallmann/genética , Leptina/genética , Hormona Luteinizante/deficiencia , Hormona Luteinizante/genética , Hormona Luteinizante/fisiología , Mutación , Neuropéptidos/genética , Folículo Ovárico/citología , Folículo Ovárico/fisiología , Ovulación , Síndrome de Prader-Willi/genética , Embarazo , Complicaciones del Embarazo/genética , Pubertad , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/genética , Receptores Acoplados a Proteínas G/genética , Receptores de Leptina/genética , Receptores de Péptidos/genética , Células Tecales/citología , Células Tecales/fisiología

Asunto(s)

Oxigenasas de Función Mixta/genética , Polimorfismo Genético , Posmenopausia , Tromboembolia Venosa/genética , Femenino , Humanos , Vitamina K Epóxido Reductasas

RESUMEN

The mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) syndrome is characterized by the association of gastrointestinal and neurological symptoms. It is a rare autosomal recessive mitochondrial disorder with multiple mitochondrial DNA deletions and/or depletion. It is caused by thymidine phosphorylase (TP) gene mutations resulting in a complete abolition of TP activity. We tested 31 unrelated patients presenting either with a complete MNGIE syndrome (8 patients), a severe intestinal pseudo-obstruction (10 patients), and multiple deletions and/or depletion of mitochondrial DNA (13 patients). All the tested patients presenting with a complete MNGIE had increased thymidine levels in plasma and urine, and no TP activity. The group with pseudo-obstruction syndrome had normal or partial reduction of TP activity. We found pathogenic mutations on TP gene only in the MNGIE syndrome group: all the MNGIE patients were compound heterozygous or homozygous for mutations in the TP gene. Eight of these mutations are yet unreported, confirming the lack of genotype/phenotype correlation in this syndrome. Enzymatic activity and thymidine level are thus rapid diagnosis tests to detect MNGIE affected patients prior to genetic testing for patients with gastrointestinal symptoms.

Asunto(s)

Encefalomiopatías Mitocondriales/genética , Mutación , Timidina Fosforilasa/genética , Adulto , Niño , ADN Mitocondrial/genética , Humanos , Seudoobstrucción Intestinal/genética , Eliminación de Secuencia , Síndrome , Timidina/sangre , Timidina/orina , Timidina Fosforilasa/metabolismo

RESUMEN

The concept of Dejerine-Sottas disease, which corresponds to presumed recessive demyelinating neuropathies with onset in infancy, remains controversial. To learn more on the subject, we performed a clinico-pathological and molecular genetic study in 15 unrelated patients with the Dejerine-Sottas phenotype seen over a 16 year period. There were 12 females and 3 males, born to asymptomatic parents. Study of the PMP22, P0 and Egr2 genes was performed in all cases and 14 underwent a nerve biopsy. First manifestations of neuropathy occurred before 3 years of age in all patients. An inherited disorder was suspected in 10 patients, because of their family history and/or disclosure of a molecular genetic defect in 4 of them. One patient had a recessively transmitted homozygous point mutation (Arg157Trp) of the PMP22 gene. A heterozygous duplication of the 17p11.2-12 segment was detected in one offspring of a consanguineous marriage. One patient carried a "de novo" heterozygous Ser72Leu substitution in the PMP22. A heterozygous double mutation of the P0 gene including a "de novo" Val42 deletion and an Ala221Thr substitution, maternally inherited, were found in an apparently sporadic case. No mutation of the Egr2 gene was identified. A neuropathy with focally folded myelin sheaths (CMT4B) was diagnosed in the nerve biopsy specimens of two patients. In five patients, the clinico-pathological findings along with the absence of an identified mutation suggested the diagnosis of chronic inflammatory demyelinating polyneuropathy of infantile onset. Our findings illustrate the genetic heterogeneity of cases with identified mutations, the scarcity of cases with "demonstrated" recessive transmission and the likelihood of early acquired chronic inflammatory demyelinating polyneuropathy in several patients.

Asunto(s)

Neuropatía Hereditaria Motora y Sensorial/genética , Neuropatía Hereditaria Motora y Sensorial/fisiopatología , Proteína P0 de la Mielina/genética , Proteínas de la Mielina/genética , Adolescente , Adulto , Niño , Electrofisiología , Femenino , Neuropatía Hereditaria Motora y Sensorial/patología , Heterocigoto , Humanos , Masculino , Mutación/genética , Fibras Nerviosas/patología , Fibras Nerviosas Mielínicas/patología , Nervio Sural/patología

RESUMEN

OBJECTIVES: Comparative study of plasma progesterone and betaHCG kinetics following surgical treatment of ectopic pregnancy. STUDY DESIGN: Prospective study involving 62 patients with tubal ectopic pregnancies. Study of the kinetics of plasma progesterone and betaHCG, and the correlation coefficient between plasma progesterone and betaHCG levels during post-operative follow-up. RESULTS: Thirty-nine patients were treated by salpingostomy and 23 by salpingectomy. Analyzing the betaHCG kinetics according to treatment revealed that both curves were convergent on day 2. Progesterone kinetics differed greatly in that they appeared "parallel and confused". Analyzing the correlation between betaHCG and progesterone levels proved the absence of a significant link. CONCLUSIONS: Studying the kinetics of plasma progesterone after surgical treatment of ectopic pregnancies revealed a fast decrease in progesterone. Statistical analysis of the progesterone concentration showed that post-operative kinetics is fully independent from that of betaHCG. Progesterone therefore cannot be substituted to betaHCG for post-operative follow-up.

Asunto(s)

Embarazo Tubario/sangre , Embarazo Tubario/cirugía , Progesterona/sangre , Gonadotropina Coriónica Humana de Subunidad beta/sangre , Trompas Uterinas/cirugía , Femenino , Humanos , Cinética , Embarazo , Estudios Prospectivos , Sensibilidad y Especificidad , Insuficiencia del Tratamiento

RESUMEN

Hereditary motor and sensory neuropathy (HMSN) is a heterogeneous group of peripheral neuropathies which are diagnosed on the basis of clinical, electrophysiological and neuropathological findings. Among the hypertrophic demyelinating neuropathies, HMSN III is the most severe. It is often associated with de novo mutations in the genes encoding for peripheral myelin proteins. While peripheral nerve hypertrophy is an expected finding in HMSN III, cranial nerve hypertrophy is exceptional. Here we describe a mutation in the PMP22 gene in a 19-year-old man with infantile onset of sensory motor polyneuropathy without family history and multiple cranial nerve hypertrophy shown by cranial magnetic resonance imaging.

Asunto(s)

Enfermedades de los Nervios Craneales/genética , Enfermedades de los Nervios Craneales/fisiopatología , Neuropatía Hereditaria Motora y Sensorial/genética , Neuropatía Hereditaria Motora y Sensorial/fisiopatología , Proteínas de la Mielina/genética , Fenilalanina/genética , Eliminación de Secuencia , Adulto , Enfermedades de los Nervios Craneales/patología , Neuropatía Hereditaria Motora y Sensorial/patología , Humanos , Imagen por Resonancia Magnética , Masculino

RESUMEN

The authors report three cases of pregnancy in women treated for bladder exstrophy. Based on a review of the literature, and the follow-up of these cases, the aim of this study was to determine the prognosis of pregnancy, which is currently possible due to the progress in antibiotherapy and surgery. Nevertheless, these pregnancies need to be carefully followed-up, not only because of the complications that may occur to the mother and the infant, but also because of the type of delivery involved.

Asunto(s)

Extrofia de la Vejiga/complicaciones , Extrofia de la Vejiga/cirugía , Complicaciones del Embarazo , Cesárea , Femenino , Humanos , Recién Nacido , Infertilidad Femenina/etiología , Embarazo , Resultado del Embarazo

RESUMEN

We describe the case of a girl with an unusual congenital phenotype, combining peculiar peripheral nerve lesions with hypomyelination, chronic intestinal pseudoobstruction, and deafness. She was found to have a de novo heterozygous frameshift mutation in the gene encoding the SOX10 transcription factor. The likely role of SOX10 in determining the fate of Schwann cells during early embryogenesis may explain the peripheral nervous system developmental disorder observed in this patient.

Asunto(s)

Proteínas de Unión al ADN/genética , Sordera/genética , Proteínas del Grupo de Alta Movilidad/genética , Seudoobstrucción Intestinal/genética , Vaina de Mielina/ultraestructura , Cresta Neural/fisiopatología , Enfermedades del Sistema Nervioso Periférico/genética , Secuencia de Aminoácidos/genética , Sordera/fisiopatología , Femenino , Humanos , Lactante , Seudoobstrucción Intestinal/fisiopatología , Cariotipificación , Datos de Secuencia Molecular , Mutación/genética , Conducción Nerviosa/genética , Conducción Nerviosa/fisiología , Enfermedades del Sistema Nervioso Periférico/patología , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Fenotipo , Factores de Transcripción SOXE , Síndrome , Factores de Transcripción

RESUMEN

Selective estradiol receptor modulators (SERMs) are specific modulators of estradiol action. They are used in therapeutics to obtain an estrogenic effect on certain cells and an antiestrogenic effect on other cells. Recent progress in the knowledge of the mechanism of action of estradiols implies that new molecules could be designed. This progress involves the cloning of a new estradiol receptor, ER beta, the discovery of co-activators and the elucidation of their molecular mechanism of action, and the crystallization of the ligand binding domain in the presence of an agonist or an antagonist.

Asunto(s)

Moduladores Selectivos de los Receptores de Estrógeno , Animales , Estradiol/farmacología , Humanos , Receptores de Estrógenos/análisis , Receptores de Estrógenos/genética , Receptores de Estrógenos/fisiología , Moduladores Selectivos de los Receptores de Estrógeno/síntesis química , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Moduladores Selectivos de los Receptores de Estrógeno/uso terapéutico

RESUMEN

Steroids effects are mediated by their receptors. These proteins define the large family of steroid hormone receptors, characterized by the presence of 3 functional domains: a transactivation domain, a DNA-binding domain and a ligand-binding domain. Receptor activation induces the modulation of transcription of specific genes, and as a consequence, the modulation of production of specific proteins. Sex steroid receptors are located in the nucleus. This nuclear localization is in fact a dynamic situation, resulting from a continuous shuttling of the receptor between the cytoplasm and the nucleus. The recent discovery that an additional estrogen receptor is present in various tissues has advanced our understanding of the mechanism underlying estrogen signalling. Non genomic effects of steroids have also been described. Sex steroids inhibit proliferation of smooth muscle cells. On the contrary, they stimulate proliferation of tumoral muscle cells. The mechanisms of sex steroid effects on cellular proliferation are complex, and may involve transcriptional or non transcriptional phenomena.

Asunto(s)

Hormonas Esteroides Gonadales/fisiología , Músculo Liso/citología , Músculo Liso/fisiología , Receptores de Esteroides/fisiología , Diferenciación Celular , División Celular , Femenino , Humanos , Leiomioma/fisiopatología , Neoplasias Pulmonares/fisiopatología , Linfangioleiomiomatosis/fisiopatología , Músculo Liso Vascular/citología , Músculo Liso Vascular/fisiología , Proteínas Nucleares/fisiología , Transcripción Genética , Neoplasias Uterinas/fisiopatología

RESUMEN

In 1926, Roussy and Lévy described a large family whose members manifested an early onset dominantly inherited gait ataxia, pes cavus, and areflexia, which was eventually associated with distal muscle atrophy, postural tremor, and minor sensory loss. Slow nerve conduction and demyelination of nerve fibers with onion bulb formations in nerve biopsy specimens led to the Roussy-Lévy syndrome (RLS) being considered a variant of demyelinating Charcot-Marie-Tooth disease (CMT-1). In the present article, we report on the long-term follow-up, on nerve biopsy findings, and on the underlying molecular genetic defect in members of the original family studied by Roussy and Lévy. All patients were able to walk during their seventh decade of life. Morphologically, a chronic demyelinating neuropathy with the remarkable aspects of a focally hypertrophic myelin sheath and major loss of myelinated fibers was observed in nerve biopsy specimens of 3 members of this family. Molecular genetic testing identified a previously unknown heterozygous missense point mutation which yielded an Asn131Lys substitution in the extracellular domain of the myelin protein zero (P0). These findings show that the Roussy-Lévy family belongs to the CMT-1B subtype and has original morphological and genetic features.

Asunto(s)

Enfermedad de Charcot-Marie-Tooth/genética , Cromosomas Humanos Par 17 , Variación Genética , Fibras Nerviosas Mielínicas/patología , Anciano , Anciano de 80 o más Años , Sustitución de Aminoácidos , Enfermedad de Charcot-Marie-Tooth/patología , Mapeo Cromosómico , Exones , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Mutación Missense , Proteína P0 de la Mielina/genética , Proteínas de la Mielina/genética , Linaje , Nervio Sural/patología , Factores de Tiempo